These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6146126)

  • 1. [Effect of beta-adrenolytic drugs on hepatic clearance of antipyrine].
    Adamska-Dyniewska H; Pruszczyński J; Wichan P
    Pol Arch Med Wewn; 1984 Feb; 71(2):71-7. PubMed ID: 6146126
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
    Adamska-Dyniewska H; Dziekański S; Pruszczyński J
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):303-7. PubMed ID: 2874117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Changes in hepatic biotransformation in patients treated with beta-adrenergic drugs and prazosin].
    Adamska-Dyniewska H; Dziekański S
    Pol Tyg Lek; 1989 Apr 10-17; 44(15-16):361-3. PubMed ID: 2626354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of combined therapy with cimetidine and (+)-cyanidanol-3 on the hepatic clearance of antipyrine].
    Adamska-Dyniewska I; Tkaczewski W; Jabłkowski M; Chojnacki J
    Pol Arch Med Wewn; 1986 Mar; 75(3):161-6. PubMed ID: 3763411
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of labetalol on antipyrine metabolism in the liver].
    Adamska-Dyniewska H; Dziekański S
    Pol Arch Med Wewn; 1984 Mar; 71(3):149-55. PubMed ID: 6739318
    [No Abstract]   [Full Text] [Related]  

  • 6. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacometabolic capacity of the liver and the effect of pancreozymin in chronic hepatitis, chronic pancreatitis and diabetes mellitus].
    Geller LI; Griaznova MV; Bulgakova OS; Kozlova ZP
    Ter Arkh; 1982; 54(2):67-9. PubMed ID: 7071776
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of vitamin C supplement on antipyrine disposition in man.
    Houston JB
    Br J Clin Pharmacol; 1977 Apr; 4(2):236-9. PubMed ID: 861139
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of prolonged oral cimetidine, ranitidine, and famotidine therapy on antipyrine elimination.
    Sakaue H; Akamatsu K; Hirabayashi Y; Sasaki T; Nakanishi K; Okada S; Kanaoka M; Nishinobu M; Masumoto S; Ohta Y
    Clin Ther; 1987; 9(6):602-6. PubMed ID: 2894244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of acute and chronic propranolol administration on antipyrine and paracetamol clearance in patients with chronic liver disease.
    Hayes PC; Bouchier IA
    Am J Gastroenterol; 1989 Jul; 84(7):723-6. PubMed ID: 2741882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipyrine clearance in pneumonia.
    Sonne J; Døssing M; Loft S; Andreasen PB
    Clin Pharmacol Ther; 1985 Jun; 37(6):701-4. PubMed ID: 4006370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The metabolic clearance rate of antipyrine: a good index for the assessment of the hepatic drug-oxidizing function in cirrhotic patients (author's transl)].
    Miguet JP; Allemand H; Joanne C; Dhumeaux D
    Nouv Presse Med; 1978 Dec; 7(46):4209-11. PubMed ID: 745958
    [No Abstract]   [Full Text] [Related]  

  • 13. Fractional clearance of bromosulfonephthalein and metabolic clearance of antipyrine. Correlative study in liver diseases.
    Couet C; Brissot P; Messner M; Delamaire D; Gie S; Bourel M
    Ann Gastroenterol Hepatol (Paris); 1984; 20(1):1-6. PubMed ID: 6529154
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly variations in the pharmacokinetics of antipyrine in calves.
    Janus K; Baranow-Baranowski S; Jakubowska D; Jankowiak D; Skrzypczak WF
    Arch Vet Pol; 1992; 32(3-4):113-8. PubMed ID: 1339566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medroxyprogesterone acetate does not induce antipyrine clearance and only weakly increases alpha 1-acid glycoprotein in beagle dogs.
    Abramson FP; Moore CF; Hill MD
    Res Commun Chem Pathol Pharmacol; 1986 Jul; 53(1):65-78. PubMed ID: 2944196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clearance of antipyrine-dependence of quantitative liver function.
    Andreasen PB; Ranek L; Statland BE; Tygstrup N
    Eur J Clin Invest; 1974 Apr; 4(2):129-34. PubMed ID: 4832718
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. II. Effect of propranolol].
    Hartleb M; Markiewicz A; Rudzki K; Nowak S; Bołdys H; Kacperek T
    Pol Arch Med Wewn; 1987 Jun; 77(6):270-5. PubMed ID: 3271279
    [No Abstract]   [Full Text] [Related]  

  • 18. Ethanol and antipyrine clearance.
    Døssing M; Andreasen PB
    Clin Pharmacol Ther; 1981 Jul; 30(1):101-4. PubMed ID: 7237890
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketoconazole does not impair antipyrine clearance in humans.
    Blyden GT; Abernethy DR; Greenblatt DJ
    Int J Clin Pharmacol Ther Toxicol; 1986 May; 24(5):225-6. PubMed ID: 3733272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.